Cryoglobulinemia: An update on classification, pathophysiology, clinical presentation, and management

Area of Science:

• Immunology
• Hematology
• Rheumatology

Background:

• Cryoglobulinemia (CG) is characterized by immunoglobulins precipitating at low temperatures.
• It presents as Type I (monoclonal) or mixed CG (MC) (Types II and III), often linked to lymphoproliferative disorders or viral infections like Hepatitis C Virus (HCV).

Purpose of the Study:

• To review the pathophysiology, clinical manifestations, and recent advances in understanding and treating cryoglobulinemia.
• To highlight the distinct features and management strategies for Type I and mixed cryoglobulinemia.

Main Methods:

• Literature review of cryoglobulinemia pathophysiology, clinical features, and therapeutic strategies.
• Synthesis of current knowledge on etiopathogenesis and treatment modalities for different CG types.

Main Results:

• Type I CG is associated with hematologic malignancies and severe cutaneous manifestations.
• Mixed CG (MC) is predominantly linked to HCV and involves B-cell activation and autoantibody production.
• Both types can cause systemic vasculopathy, requiring tailored management including antiviral therapy for MC and addressing underlying malignancy in Type I.

Conclusions:

• Effective cryoglobulinemia management necessitates a multidisciplinary approach targeting both the underlying cause and clinical complications.
• Therapeutic options include antivirals, corticosteroids, immunomodulators, and plasma exchange, chosen based on CG type and severity.